In the latest trading session, 0.4 million Iterum Therapeutics Plc (NASDAQ:ITRM) shares changed hands as the company’s beta touched 2.29. With the company’s most recent per share price at $1.64 changed hands at -$0.01 or -0.60% at last look, the market valuation stands at $45.13M. ITRM’s current price is a discount, trading about -84.15% off its 52-week high of $3.02. The share price had its 52-week low at $0.81, which suggests the last value was 50.61% up since then. When we look at Iterum Therapeutics Plc’s average trading volume, we note the 10-day average is 0.71 million shares, with the 3-month average coming to 3.01 million.
Analysts gave the Iterum Therapeutics Plc (ITRM) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ITRM as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Iterum Therapeutics Plc’s EPS for the current quarter is expected to be -0.24.
Iterum Therapeutics Plc (NASDAQ:ITRM) trade information
Instantly ITRM was in red as seen in intraday trades today. With action -13.68%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -7.34%, with the 5-day performance at -13.68% in the red. However, in the 30-day time frame, Iterum Therapeutics Plc (NASDAQ:ITRM) is -28.69% down. Looking at the short shares, we see there were 2.53 million shares sold at short interest cover period of 0.46 days.
Iterum Therapeutics Plc (ITRM) estimates and forecasts
Data shows that the Iterum Therapeutics Plc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 2.19% over the past 6 months, a 59.80% in annual growth rate that is considerably higher than the industry average of 16.20%.
2 analysts are of the opinion that Iterum Therapeutics Plc’s revenue for the current quarter will be 1.34M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 19.62%. The 2025 estimates are for Iterum Therapeutics Plc earnings to increase by 65.98%.
ITRM Dividends
Iterum Therapeutics Plc is expected to release its next quarterly earnings report in February.
Iterum Therapeutics Plc (NASDAQ:ITRM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.81% of Iterum Therapeutics Plc shares while 8.99% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 9.15%. There are 8.99% institutions holding the Iterum Therapeutics Plc stock share, with BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC the top institutional holder. As of 2024-06-30, the company held 0.0004% of the shares, roughly 66.0 ITRM shares worth $76.0.
ANCORA ADVISORS, LLC holds the second largest percentage of outstanding shares.
With 12.37 shares estimated at $20186.0 under it, the former controlled 0.04% of total outstanding shares.
